# Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Source: https://onco.cc/trials/nct03459170/  
OnCo record `nct03459170` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, active and no longer recruiting.

## Summary

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant is a phase 1 interventional study registered as NCT03459170 by Bellicum Pharmaceuticals, with 15 participants planned, started 2018-02-01. Conditions recorded: Hematologic Malignancy. Interventions recorded: BPX-501 T cells and rimiducid.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03459170
- Phase: 1
- Setting: A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant
- Sponsor: Bellicum Pharmaceuticals
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT03459170: https://clinicaltrials.gov/study/NCT03459170

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Rivogenlecleucel](https://onco.cc/drugs/rivogenlecleucel/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/)

---
JSON: https://onco.cc/api/v1/entities/nct03459170.json